Both healthy and systemic sclerosis cells turn into fibroblasts in the same way when exposed to PDGF-BB, suggesting this growth factor doesn't cause the disease through MSC dysfunction.
Evidence from Studies
Supporting (1)
Community contributions welcome
Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
When exposed to PDGF-BB, both healthy cells and cells from people with systemic sclerosis turned into fibroblasts in the same way — so the growth factor isn’t causing the disease because of faulty cells. The problem lies elsewhere, likely with another signal called TGF-β1.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether PDGF-BB induces identical fibroblastic responses in MSCs across all SSc subtypes and whether this response correlates with clinical fibrosis.
A systematic review and meta-analysis of all published studies comparing PDGF-BB-induced fibroblastic differentiation (collagen, migration, proliferation) in MSCs from SSc patients versus healthy controls, with pooled effect sizes and subgroup analysis by disease subtype.
Whether inhibiting PDGF-BB signaling reduces fibrosis in SSc patients despite normal MSC responses.
A double-blind RCT of 120 SSc patients with skin fibrosis, randomized to receive a PDGF receptor inhibitor (e.g., nintedanib) or placebo for 48 weeks; primary outcome is change in mRSS, with secondary outcomes including serum PDGF-BB levels and MSC fibroblastic markers.
Whether PDGF-BB levels in serum correlate with fibrosis progression in SSc despite normal MSC responses.
A prospective cohort of 200 SSc patients, measuring serum PDGF-BB levels at baseline and annually for 5 years; primary outcome is change in FVC and mRSS, with secondary analysis of MSC fibroblastic response to PDGF-BB at baseline.
Whether PDGF-BB-induced fibroblastic differentiation in MSCs differs between SSc patients with and without severe fibrosis.
A case-control study comparing PDGF-BB-induced collagen secretion, migration, and proliferation in MSCs from 50 SSc patients with severe fibrosis and 50 with mild disease, matched for age, sex, and disease duration.
Whether PDGF-BB-induced MSC fibroblastic response correlates with current fibrosis severity in SSc patients.
A cross-sectional analysis of MSCs from 130 SSc patients, measuring collagen secretion and migration after PDGF-BB exposure and correlating with mRSS and FVC at the time of bone marrow aspiration.